HCK and kidney disorder: We described here BT424, a relatively selective inhibitor of HCK and BT424 does not affect podocyte injury and therefore, we believe that BT424 is a better drug to target HCK as an anti-inflammatory and anti-fibrosis therapy in patients with kidney disease.